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Summary  26 
Due to increasing microbial resistance, pressure on veterinarians is mounting to adhere to 27 
responsible use of antimicrobial drugs. Antimicrobials are frequently included in the 28 
treatment of systemically ill horses due to the strong likelihood of an infection and the innate 29 
difficulties in differentiating systemic inflammation secondary to non-infectious from 30 
infectious causes. In light of increasing antimicrobial drug resistance and the potential 31 
negative impact of antimicrobials on equine patients, every attempt should be made to 32 
identify non-infectious disease, choose first line antimicrobials and discontinue treatment as 33 
soon as possible. In most cases, a short duration of antimicrobial therapy ranging from a 34 
single dose (for example pre-operatively) to 24-72h might be sufficient with long-term 35 
treatment being rarely required. The article aims to provide practical guidelines for 36 
antimicrobial drug usage in critically ill adult horses by describing ancillary diagnostic aids 37 
that can help establishing whether or not an infection is present, discussing commonly 38 
encountered pathogens and their typical antimicrobial drug sensitivity patterns and providing 39 












Critical or intensive care in people extends beyond internal medicine dealing with a subset of 52 
patients with immediate life-threatening conditions (Marshall, Bosco et al. 2017). In equine 53 
medicine, the term is used more loosely, often referring to animals that require more intense 54 
support than the average equine patient or simply animals with systemic and potentially life-55 
threatening disease (Lascola, Vander Werf et al. 2017). Many critical illnesses in horses are 56 
associated with infection or with significant absorption of bacterial products and toxins 57 
causing activation of the inflammatory and coagulation system. Clinically, both scenarios are 58 
often indistinguishable. Although not effective against purely inflammatory conditions, 59 
antimicrobials are frequently included in the treatment of these animals due to the strong 60 
likelihood of an infection and the innate difficulties in differentiating systemic inflammation 61 
secondary to non-infectious causes from infections. However, due to increasing microbial 62 
resistance, pressure on veterinarians is mounting to adhere to responsible use of antimicrobial 63 
drugs. A recent study in a UK referral hospital over a ten-year period demonstrated an 64 
increase in prevalence of extended spectrum beta lactamase (ESBL)-producing E. coli as well 65 
as increased antimicrobial resistance to frequently used antimicrobials including doxycycline, 66 
gentamicin and 3rd generation cephalosporins (Isgren, Edwards et al. 2019); other studies 67 
have confirmed increasing resistance in bacteria isolated from horses, particularly after 68 
antimicrobial therapy (Maddox, Williams et al. 2011, Theelen, Wilson et al. 2020). 69 
Unnecessary or unnecessarily long use of antimicrobial drugs enhances development of 70 
resistance in pathogens, increases the cost of treatment and exposes the patient to possible 71 
side effects, most noticeably disruption of the intestinal microbiome and antimicrobial-72 
induced diarrhoea (Gronvold, L'Abee-Lund et al. 2010, Johns, Verheyen et al. 2012, Barr, 73 
Waldridge et al. 2013, Costa, Stampfli et al. 2015). Every attempt should therefore be made 74 
to limit their use. This can be achieved by making every effort to identify non-infectious 75 
disease, choosing first line antimicrobials in the first instance and discontinuing treatment as 76 
quickly as possible. The use of drugs of veterinary and human medical importance including 77 
3rd-, 4th- and 5th-generation cephalosporins, glycopeptides (vancomycin), quinolones 78 
(enrofloxacin, marbofloxacin), macrolides (erythromycin, azithromycin, clarithromycin), 79 
newer, extended spectrum penicillins and carbapenems, should be avoided unless there is 80 
confirmed infection with a susceptible organism or for the treatment of life-threatening 81 
conditions unlikely to respond to first line choices (Raidal 2019). Many clinicians feel that 82 
some  antimicrobials such as vancomycin and carbapenems should not be used in animals 83 
under any circumstances. Even drugs commonly used in horses and other veterinary species 84 
such as gentamicin, rifampicin, ampicillin and amoxicillin-clavulanic acid are now on the 85 
World Health Organisation list of critically important antimicrobials which could lead to 86 
restrictions of their use in veterinary medicine in the future 87 
(https://www.who.int/foodsafety/publications/antimicrobials-sixth/en/). In most cases, a short 88 
duration of antimicrobial therapy ranging from a single dose (for example pre-operatively) to 89 
24-72h might be sufficient with long-term treatment being rarely required. Recent studies in 90 
human medicine have shown impressive reductions in antimicrobial resistance with a 91 
reduction of not only overall use but also with a decrease in days of antimicrobial therapy 92 
highlighting the importance of shortening treatment (Dona, Barbieri et al. 2020). 93 
Unfortunately, in everyday life clinicians’ efforts are often impeded by the inability to 94 
differentiate infectious from non-infectious conditions due to non-specific clinical signs, 95 
difficulties of culturing relevant pathogens, financial limitations impeding repeated testing 96 
and pressure from the owners, yard managers or trainers to use antimicrobial drugs. To 97 
further compound the issue, prospective studies investigating responsible antimicrobial drug 98 
use in horses are lacking and most guidelines are based either on information gained from 99 
human research or, more commonly, clinical impressions, which are subjective and unreliable 100 
at best.  101 
 102 
Identifying the need for antimicrobial treatment 103 
Antimicrobial drugs are unlikely to have a significant beneficial effect against anything but 104 
infectious diseases, usually bacterial or rarely fungal or protozoal in origin. Although some 105 
antimicrobials such as tetracyclines also have anti-inflammatory effects (Pradhan, Madke et 106 
al. 2016), their use for purely inflammatory conditions is controversial and use of classic anti-107 
inflammatories such as non-steroidal anti-inflammatory drugs is far more appropriate. 108 
Unfortunately, it is extremely difficult to reliably rule out an infectious process. Clinical 109 
examination findings are non-specific and rarely help with the differentiation. Heart and 110 
respiratory rates are greatly influenced by pain, cardiovascular compromise and systemic 111 
inflammation making them much more useful in judging disease severity rather than an 112 
infectious or non-infectious nature. While the presence of a fever increases the clinical 113 
suspicion of an infection, it is by no means conclusive as inflammation, hyperthermia, 114 
neoplasia or significant tissue trauma can also lead to an increase in rectal temperature. 115 
Equally, the absence of a fever does not rule out even severe infection. Haematology and 116 
acute phase protein concentrations such as fibrinogen or serum amyloid A (SAA) can be 117 
difficult to interpret as increases in concentrations can be triggered by infectious and non-118 
infectious inflammatory conditions alike (Westerman, Tornquist et al. 2015, Long and Nolen-119 
Walston 2020). Although a statistical difference in SAA concentrations between infectious 120 
and non-infectious airway disease has been reported, there was significant overlap between 121 
groups and in some horses with infection, SAA concentrations remained low or at 0mg/L 122 
(Viner, Mazan et al. 2017). In adult horses, leucopaenia is commonly observed with 123 
significant inflammation, often originating from the gastrointestinal system, and caused by 124 
margination and extravasation of leucocytes at the site of inflammation. It does not 125 
necessarily indicate the presence of infection or the need for antimicrobial treatment. 126 
Leucocytosis in mature horses can be observed with inflammatory, infectious and neoplastic 127 
conditions or following administration of corticosteroids and is therefore also of limited use 128 
when trying to differentiate infectious from non-infectious conditions (Targowski 1975, 129 
White, Affolter et al. 2009, Meichner, Kraszeski et al. 2017). As immediate treatment is 130 
usually required, the clinician needs to make an educated guess whether or not infection is 131 
likely and antimicrobial drugs are needed. Many equine viral and some bacterial diseases can 132 
be diagnosed by polymerase chain reaction (PCR) with results often being available the 133 
following day. Cytological samples, submitted in addition to samples for culture and 134 
sensitivity, can be of great value when trying to rule out an infectious aetiology as results are 135 
much quicker available compared to culture and are not compounded by difficult culturing 136 
processes. In cases where clinicians have already initiated antimicrobial treatment but PCR or 137 
cytological results do not support an infection or identify a viral cause for the disease, 138 
antimicrobial treatment should be discontinued immediately. The old concept that “a course 139 
of antibiotics needs to be finished to avoid development of resistance” is incorrect and 140 
obsolete. The perception that stopping antibiotic treatment early encourages antibiotic 141 
resistance is not supported by evidence, while increasing length of antimicrobial use 142 
undoubtedly increases the risk of resistance development (Llewelyn, Fitzpatrick et al. 2017). 143 
In contrast, reducing the length of treatment has a significant effect on decreasing previously 144 
existing resistance (Dona, Barbieri et al. 2020). Submitting samples for culture and sensitivity 145 
remains essential as results will provide guidance for further antimicrobial choices if the 146 
initial treatment fails to resolve the infection. Over time, results also provide invaluable 147 
insight into regional pathogens and their antimicrobial sensitivity patterns (Johns 2017, 148 
Raidal 2019). Reports on commonly identified bacteria, the organ system they were cultured 149 
from and their sensitivity patterns can often be obtained from regional laboratories providing 150 
insight into local resistance patterns. 151 
Limiting the duration of antimicrobial treatment in proven infections can be 152 
challenging. Fear of negating a treatment success often leads clinicians to prolong use of 153 
antimicrobial drugs in clinically apparently recovered patients. Unfortunately, studies to 154 
identify the minimum effective treatment duration have rarely been performed, even in 155 
people, leave alone in horses. Current guidelines are therefore often purely based on absence 156 
of data for efficacy of shorter courses rather than the explicit need for long therapies 157 
(Llewelyn, Fitzpatrick et al. 2017). In the past, many clinicians have used return to normal 158 
haematologic parameters or normal concentrations of acute phase proteins, mainly 159 
fibrinogen, as a marker to safely discontinue antimicrobial treatment. Plasma fibrinogen has a 160 
relatively long half-life of 4.1-5.2 days in horses and awaiting normal concentrations likely 161 
results in over-treatment (Coyne, Hornof et al. 1985). Return to normothermia, improved 162 
appetite and return of normal demeanour might be better indicators that further treatment is 163 
not necessary. It is also common practice to initially treat systemically ill horses with 164 
injectable antimicrobial drugs for 48-72h, often in a hospital setting, followed by continued 165 
oral treatment at home. In most cases, this continuation of antimicrobial treatment is not 166 
necessary. An alternative approach is stopping antimicrobial treatment after 48-72h and 167 
monitoring the patient for another 24h whilst still in the hospital (or close monitoring by the 168 
owner at home). The additional cost for hospitalisation are at least partially offset by saving 169 
cost for drugs. Should signs of infection re-occur, such as recurrence of a fever, a decrease in 170 
appetite or change in demeanour, treatment can easily be re-initiated. If not, the patient can be 171 
discharged off all medications.  172 
 173 
Responsible use of antimicrobials in gastrointestinal diseases 174 
Horses with a primary complaint of colic rarely require antimicrobial therapy. The 175 
examination is focused on establishing the nature of the problem and deciding whether 176 
medical or surgical options should be pursued. Horses with fever and vague colic signs with 177 
or without diarrhoea often suffer from intestinal inflammation such as enteritis and colitis or 178 
from peritonitis. There is no evidence that antimicrobial therapy is beneficial in cases of 179 
intestinal inflammation. Some clinicians even feel that their use is contraindicated, 180 
considering the negative impact of antimicrobials on the microbiota, adding further insult to 181 
an already disturbed microbial environment (Harlow, Lawrence et al. 2013, Shaw and 182 
Stampfli 2018). Exceptions include colitis caused by Neorickettsia risticii (Potomac horse 183 
fever) or rare cases of Lawsonia intracellularis in adult horses (Page, Slovis et al. 2014) 184 
where treatment with oxytetracycline is indicated. Antimicrobial treatment has also been 185 
considered for clostridia-associated diarrhoea. An association between metronidazole 186 
treatment and survival was identified in horses diagnosed with clostridial diarrhoea but 187 
metronidazole had no effect on survival of horses with non-clostridia associated diarrhoea 188 
(Weese, Toxopeus et al. 2006).  However, administration of metronidazole has also been 189 
linked with identification of metronidazole-resistant Clostridium difficile strains. These 190 
strains are suspected to be more virulent and carried an increased risk of mortality compared 191 
to horses infected with metronidazole-susceptible strains (Magdesian, Dujowich et al. 2006, 192 
Schoster and Staempfli 2016). Considering the controversial evidence and pressure of 193 
building resistance refraining from use of metronidazole in horses with diarrhoea might be 194 
preferable. Bacteraemia has been reported in adult horses with colitis and is sometimes 195 
considered as a reason for use of antimicrobials in these patients. However, prior treatment or 196 
treatment during hospitalization with antimicrobial drugs did not protect horses from 197 
development of bacteraemia arguing against their use (Johns, Tennent-Brown et al. 2008). 198 
 199 
Peritonitis, a less common but potentially life life-threatening disease, is also often associated 200 
with fever and vague intestinal signs. Peritoneal fluid analysis can quickly rule peritonitis in 201 
or out and is a procedure that can be easily performed in the field. The gross appearance of 202 
the sample can be misleading and an accurate cell count and protein concentration should 203 
always be obtained to avoid misinterpretation. An increased cell count (>20-50x109/L) and 204 
protein concentration (>25g/L) in a horse with compatible clinical signs is sufficient to make 205 
a diagnosis of peritonitis, usually bacterial in origin. However, intestinal necrosis and 206 
infarction, for example secondary to migrating Strongylus vulgaris larvae can also result in 207 
peritonitis (Pihl, Nielsen et al. 2018). Best treatment options and prognosis for peritonitis 208 
depend highly on the underlying cause and presenting signs. Horses with Actinobacillus 209 
equuli-associated or so called idiopathic peritonitis (defined as peritonitis without identifiable 210 
cause such as trauma, abdominal surgery, intestinal necrosis, infarction or rupture or 211 
neoplasia) with little or no systemic compromise have a much better prognosis and might 212 
respond to monotherapy with first line antimicrobials (Henderson, Mair et al. 2008, Odelros, 213 
Kendall et al. 2019). In contrast, surgical exploration should be strongly considered in any 214 
horse with a history of previous trauma or abdominal surgery, a palpable or 215 
ultrasonographically visible mass or suspicion of foreign body ingestion. In a recent study of 216 
horses with wire ingestion all survivors underwent exploratory laparotomy highlighting the 217 
fact early surgical intervention can be life-saving (Marley, Soffler et al. 2018). Surgical 218 
exploration might also be indicated in horses non-responsive to medical treatment within 219 
48h-72h to exclude the presence of significant intestinal compromise or other primary disease 220 
process (Pihl, Nielsen et al. 2018). The benefits of surgery include identification and possible 221 
correction of an underlying cause and recognition of cases with a poor prognosis, decreasing 222 
the need for prolonged or ineffective use of antimicrobials.  223 
Intra- or extracellular bacteria can be identified in 17-53% of peritoneal fluid samples 224 
(Hawkins, Bowman et al. 1993, Matthews, Dart et al. 2001, Odelros, Kendall et al. 2019) and 225 
pleomorphic gram-negative rods might be indicative of Actinobacillus equuli peritonitis 226 
(Matthews, Dart et al. 2001). In an older study, the presence of bacteria in peritoneal samples 227 
was associated with non-survival (Hawkins, Bowman et al. 1993) but this is likely different 228 
for idiopathic cases and cases of A. equuli peritonitis. For these horses, the prognosis is 229 
usually good and microscopic presence of bacteria should not be interpreted as a worse 230 
prognostic indicator (Matthews, Dart et al. 2001, Odelros, Kendall et al. 2019). Bacterial 231 
peritonitis secondary to release of bacteria from the intestine usually results in mixed 232 
infections with anaerobes and Enterobacteriaceae predominating, most commonly E. coli. 233 
(van den Bogaard 1990, Davis 2003, Henderson, Mair et al. 2008). Gram positive bacteria 234 
might also be present and this should be considered when choosing antimicrobial therapy 235 
(Hawkins, Bowman et al. 1993). Penicillin remains a good first line choice for gram positive 236 
infections and most anaerobes. Susceptibility patterns of gram negative bacteria are more 237 
difficult to predict. Although increasing resistance can be problematic (Reuss and Giguere 238 
2015) aminoglycosides remain a good initial choice. Early data indicated that penicillin-239 
resistant Bacteroides spp. were isolated from 10-20% of equine peritonitis cases. A 240 
combination of penicillin, gentamicin and metronidazole has therefore traditionally been 241 
recommended while awaiting culture and sensitivity findings and use of this combination 242 
resulted in a reported survival rate of 86% in horses with peritonitis (Davis 2003, Henderson, 243 
Mair et al. 2008, Nogradi, Toth et al. 2011). However, in a more recent study, 91% of horses 244 
with idiopathic peritonitis without signs of systemic inflammation responded to penicillin 245 
alone. The remaining cases were predominately treated with penicillin and gentamicin and 246 
only 1% (n=2) received a combination of penicillin, gentamicin and metronidazole with an 247 
overall survival rate of 94% (Odelros, Kendall et al. 2019). Similarly, 61% of horses with 248 
Actinobacillus equuli infection respond to penicillin alone; the reminder to penicillin and 249 
gentamicin (Matthews, Dart et al. 2001). In light of these findings, it might be appropriate to 250 
use penicillin as monotherapy in horses with suspected Actinobacillus equuli or idiopathic 251 
peritonitis that show little evidence of systemic inflammation or cardiovascular compromise. 252 
Should the clinical condition fail to improve within 24h, addition of gentamicin might be 253 
indicated. In horses with predisposing factors or systemic compromise, a combination of 254 
penicillin, gentamicin and metronidazole and consideration of surgical exploration if the 255 
condition fails to improve would be appropriate. The use of abdominal lavage with or without 256 
closed-suction abdominal drains has been described in horses with peritonitis (Nieto, Snyder 257 
et al. 2003, Nogradi, Toth et al. 2011). Further studies are necessary to determine whether 258 
both techniques improve the outcome or decrease the length for antimicrobial therapy. 259 
Clinical signs and repeated peritoneal fluid analysis are probably the most useful tools 260 
when trying to establish whether therapy is successful and when treatment can be 261 
discontinued. Repeated abdominocenteses have no effect on peritoneal cell counts 262 
(Schumacher, Spano et al. 1985) and can be performed every 24-48h, or more frequently, as 263 
required by the case. The cell count should be substantially reduced but does not need to be 264 
normal before antimicrobial drugs can be discontinued as inflammation is likely to persist 265 
longer than infection. The author uses an arbitrary cut of point of a nucleated cell count of 266 
<10-20 x109/L before discontinuing antimicrobial drugs which appears to be clinically safe. 267 
Enterocentesis can increase the cell count significantly, up to 113±88 x109/L, and will make 268 
interpretation of samples impossible for the next 3-4 days (Schumacher, Spano et al. 1985). 269 
Intraperitoneal antimicrobial treatment administered via an intraperitoneal catheter has 270 
experimentally achieved higher peritoneal fluid concentrations than intravenous 271 
administration; however, the clinical usefulness and negative side effects still need to be fully 272 
evaluated before this can be recommended (Alonso, Peccinini et al. 2018).  273 
 274 
Responsible use of antimicrobials in respiratory diseases 275 
The history and general examination can help differentiate non-infectious from infectious 276 
respiratory disease. A horse with a chronic cough that is bright, alert and still performing, 277 
although not quite as well as usual, is unlikely to have an infectious pneumonia. Adventitious 278 
lung sounds are mainly caused by bronchoconstriction and mucus and exudate accumulation 279 
and can be present in infectious and non-infectious diseases alike. In contrast, a horse with 280 
fever and adventitious lung sounds that has recently travelled or suffered from choke should 281 
be suspected of having an infectious pneumonia or pleuropneumonia. Even if a horse with 282 
such a history is normothermic and has normal thoracic auscultatory findings significant 283 
intrathoracic disease cannot be ruled out and further diagnostics are indicated. Thoracic 284 
ultrasonography is a quick and easy way to rapidly identify infectious pneumonia and 285 
pleuropneumonia. If no areas of consolidation, free pleural fluid or large amounts of comet 286 
tails are visualised, a significant intrathoracic infection is highly unlikely. Cytological 287 
examination of a tracheal lavage or pleural fluid sample are very helpful in differentiating 288 
infectious from non-infectious respiratory conditions and add invaluable information. While 289 
often marked neutrophilic inflammation is common in infectious and non-infectious 290 
conditions, number and location of bacteria (intra- or extracellular), morphology and gram 291 
stain are helpful in identifying infections and essential for correct interpretation of culture 292 
results. Cases of bacterial pneumonia usually show an abundance of intra- and extracellular 293 
bacteria and profuse bacterial growth. A positive bacterial culture from a sample with 294 
neutrophilic inflammation but no or very few visible bacteria is in the vast majority of cases 295 
indicative of non-infectious airway inflammation such as equine asthma, particularly if 296 
growth is scant. These cases will likely respond to environmental management and/or anti-297 
inflammatory treatment alone without the need for any antimicrobial treatment.  298 
In respiratory tract infections, Streptococcus equi subsp. zooepidemicus is one of the 299 
most commonly isolated gram positive pathogens (Arroyo, Slovis et al. 2017, Carvallo, Uzal 300 
et al. 2017). Streptococcus spp. are almost always sensitive to penicillin which is therefore 301 
one of the cornerstones in treatment of respiratory infections in horses (Reuss and Giguere 302 
2015). Other penicillin-susceptible organisms include most gram-positive and gram-negative 303 
anaerobic bacteria with the noticeable exception again being Bacteroides fragilis. Penicillin-304 
resistant Bacteroides spp. were isolated from approximately 8% of pleuropneumonia cases 305 
(Hirsh and Jang 1987, Tomlinson, Reef et al. 2015). A foul smell, as it is often noted when 306 
draining pleural effusions, has been associated with anaerobic bacterial involvement even if 307 
no anaerobic organisms are isolated (Popp 1977, Ashford, Plant et al. 1984, Brook 2008, 308 
O'Brien 2012). Inadequate or delayed sample handling significantly reduces chances of 309 
culturing anaerobic organisms as exposure to oxygen for any length of time can damage or 310 
kill anaerobic bacteria (Brook 2008, Strobel 2009). Many clinicians therefore include 311 
metronidazole in their treatment regime if chances of an anaerobic infection are high. Gram 312 
negative bacteria involved in equine pleuropneumonia are variable but E. coli, Klebsiella, 313 
Pseudomonas and Actinobacillus have been isolated (Arroyo, Slovis et al. 2017). Either 314 
penicillin and gentamicin (pneumonia and pleuropneumonia without overt evidence of 315 
anaerobic infection) or a combination of penicillin, gentamicin and metronidazole (strong 316 
suspicion of anaerobic involvement) is typically recommended while awaiting culture and 317 
sensitivity findings (Davis 2003, Henderson, Mair et al. 2008, Nogradi, Toth et al. 2011). In a 318 
recent study, 92% of respiratory samples from ambulatory practice submitted to a laboratory 319 
in the South of England were sensitive to the combination of penicillin and gentamicin and 320 
87% to trimethoprim-sulfamethoxazole. Sensitivities of respiratory samples submitted from a 321 
referral hospital to the same laboratory were slightly lower but still very acceptable with 83% 322 
being susceptible to penicillin and gentamicin and 75% to trimethoprim-sulfamethoxazole 323 
(Potier and Durham 2019).  324 
Although available information is limited and highly dependent on the geographical 325 
region, it is questionable whether 3rd or 4th generation cephalosporins would offer a 326 
significant treatment advantage over the combination of penicillin and gentamicin (Toombs-327 
Ruane, Riley et al. 2015, Awosile, Heider et al. 2018, Potier and Durham 2019). Considering 328 
their reserved status, 3rd or 4th generation cephalosporins should only be used if indicated by 329 
culture and sensitivity when first line choices are not available. Enrofloxacin should not be 330 
used as stand-alone or first line therapy as it has no activity against Streptococcus spp. and 331 
anaerobes and, as a fluorquinolon, is a reserved antimicrobial drug. If first line choices do not 332 
improve the condition within 48-72h enrofloxacin could be used as a substitute for 333 
gentamicin if indicated by culture and sensitivity results in life-threatening disease due to its 334 
greater activity against Enterobacteriaceae, better penetration into phagocytic cells and 335 
tissues, and better activity in purulent material (Reuss and Giguere 2015). In the recent UK 336 
based study, no predictable efficacious second choice antimicrobial was identified for 337 
respiratory isolates resistant to the first-line antimicrobials highlighting the importance of 338 
obtaining a culture and sensitivity results early in the disease process (Potier and Durham 339 
2019). 340 
Pneumonia cases without significant tissue damage often only require a short course 341 
(2-4 days) of antimicrobials. Resolution of clinical signs or, ideally, repeat cytological 342 
evaluation of a repeated tracheal lavage can be used for guidance. Determining a safe point 343 
for discontinuation of antimicrobial treatment in pleuropneumonia cases is much more 344 
difficult as tissue damage is often extensive and abscess formation is common. Treatment for 345 
a minimum of 10 days or until clinical signs and diagnostic imaging findings indicate 346 
resolution has been recommended (Reuss and Giguere 2015, Raidal 2019). Although this is 347 
not supported by any scientific evidence, it offers a reference point, keeping in mind that 348 
discontinuation of treatment after 2-4 days should be considered in cases with minimal tissue 349 
damage.  350 
 351 
In summary, the desire to protect individual patients often leads veterinarians to use 352 
antimicrobial drugs “just in case” and to extend antimicrobial treatment for longer than 353 
necessary. Using easily available diagnostic tools such as cytology and ultrasonography can 354 
help identifying animals with a high chance of bacterial disease. Restricting the use of 355 
antimicrobial drugs to these horses and decreasing treatment duration, even if only by a 356 
couple of days, will reduce resistance development and benefit patients and the profession. 357 
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